SAN Sanofi

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

COMBINED GENERAL MEETING OF APRIL 30, 2024

AVAILABILITY OF PREPARATORY DOCUMENTS

The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris.

The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the website of the Bulletin des Annonces Légales ObligatoiresBALO” () on March 15, 2024, bulletin n°33.

The notice of meeting (avis de convocation) will be published on the website of the Bulletin des Annonces Légales ObligatoiresBALO” () on April 12, 2024.

The preparatory documents for this meeting will be made available to the shareholders in accordance with the applicable legal and regulatory provisions.

For registered shareholders, you will receive your notice of the General Meeting directly by post or by e-mail, depending on your choice. To request additional documents, you must complete the document request form on page 61 of the notice of meeting and return it to Uptevia, Assemblées Générales – 90-110 esplanade du Général de Gaulle – 92931 Paris La Défense CEDEX, no later than April 25, 2024.

For bearer shareholders, you should contact your financial intermediary.

In accordance with Article R. 22-10-23 of the French Commercial Code, the preparatory documents for this meeting are available on the Company’s website: .

We invite you to regularly consult the “Annual General Meetings” section of our website, which will be updated with any changes regarding the participation in the meeting.

* * *

Attachment



EN
08/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)

This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...

 PRESS RELEASE

Press Release: Beyfortus real-world evidence published in The Lancet s...

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...

 PRESS RELEASE

Communiqué de presse : Des données de vie réelle concernant Beyfortus ...

Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus (nirsevimab) a permis de réduire sensiblement les infections des voies respiratoires inférieures dues au VRS chez les nourrissons, de même que les hospitalisations, au cours de la saison virale 2023-2024, compa...

Sanofi: 1 director

A director at Sanofi bought 1,000 shares at 91.380EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

 PRESS RELEASE

Press Release: Annual General Meeting of April 30, 2024

Press Release: Annual General Meeting of April 30, 2024 Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2024, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the indi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch